Manufacturer record
Agron Remedies Pvt. Ltd. Sarverkhera: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
10 batches manufactured by Agron Remedies Pvt. Ltd. Sarverkhera (Uttarakhand) were declared Not of Standard Quality between August 2025 and April 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
10 records linked to Agron Remedies Pvt. Ltd. Sarverkhera in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Ibuprofen and Paracetamol Tablets IP | TB251005Mfg 2025-12 · Exp 2027-11 | The sample fails in the Test for DescriptionDescription | MDTL KathuaState lab | Apr 2026 |
| Flunixin Meglumine Injection 50mg/ml | AFM-02Mfg 2025-10 · Exp 2027-09 | DescriptionDescription | DTL, Bengaluru, KarnatakaState lab | Apr 2026 |
| Amikacin Injection IP 100 mg | LI25292Mfg 2025-09 · Exp 2027-08 | The sample does not conform to I.P. with respect to test for Particulate matter and is also not of standard quality for The reason stated under Description.Description | CDL, KolkataCDSCO lab | Dec 2025 |
| Cefixime Oral suspension IP | DS250075Mfg 2025-06 · Exp 2027-05 | The Sample Does not conform to the IP with respect to AssayAssay | DTL, JaipurState lab | Nov 2025 |
| Atorvastatin Calcium Tablets IP 40 mg | ART-07Mfg 2024-04 · Exp 2026-03 | The sample does not conform to claim as per IP 2022 in respect to the Test of DissolutionDissolution | RDTL,ChandigarhCDSCO lab | Nov 2025 |
| Ibuprofen and Paracetamol Tablets IP | NCJ-02Mfg 2025-04 · Exp 2027-03 | The sample fails in the Test for Description of Tablets.Description | MDTL Kathua,Jammu and KashmirState lab | Oct 2025 |
| Ciprofloxacin Tablets IP 500 mg | TB250356Mfg 2025-05 · Exp 2027-04 | The sample fails in the Test for Description of Tablets.Description | MDTL Kathua,Jammu and KashmirState lab | Oct 2025 |
| Tobramycin Eye Drops 0.3% (Opthalmic Use Only | EYC-50Mfg 2024-04 · Exp 2026-03 | Description and AssayAssay | DTL, JaipurState lab | Aug 2025 |
| Tobramycin Eye Drops 0.3% (Opthalmic Use Only | EYC-54Mfg 2024-05 · Exp 2026-04 | Description and AssayAssay | DTL, JaipurState lab | Aug 2025 |
| Tobramycin Eye Drops 0.3% (Opthalmic Use Only | EYC-51Mfg 2024-04 · Exp 2026-03 | Description and AssayAssay | DTL, JaipurState lab | Aug 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.